Reported about 16 hours ago
Lake Street Capital has reaffirmed a Buy rating and $30 target price for ClearPoint, highlighting the potential impact of AMT-130, an experimental gene therapy for Huntington's disease developed by uniQure. With the FDA's expedited approval process in sight, AMT-130 could significantly enhance ClearPoint's financial prospects, given its associated high-value disposables. This regulatory progress may clarify ClearPoint's role in advancing gene therapy and neurosurgery, marking a pivotal moment for the company.
Source: YAHOO